Teresa Limle
Psychiatric/Mental Health · Saint Joseph, MONPI 1962280537
Payments from drug & device makers
Across 183 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$595
- Vanda Pharmaceuticals Inc.$557
- Johnson & Johnson$368
- AbbVie$349
- Teva Pharmaceuticals USA, Inc.$335
- Neurocrine Biosciences, Inc.$275
- plus $896 from 8 others
What the payments were for
- Food & beverage$3,25596%
- Education$1194%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 23 | $595 |
| Vanda Pharmaceuticals Inc. | 23 | $557 |
| Johnson & Johnson | 10 | $368 |
| AbbVie | 25 | $349 |
| Teva Pharmaceuticals USA, Inc. | 14 | $335 |
| Neurocrine Biosciences, Inc. | 16 | $275 |
| Alkermes, Inc. | 10 | $229 |
| Supernus Pharmaceuticals, Inc. | 37 | $180 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $149 |
| Lundbeck LLC | 7 | $130 |
| E.r. Squibb & Sons, L.L.C. | 3 | $69 |
| Biogen | 3 | $59 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Indivior Inc. | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fanapt$241
- SPRAVATO$124
- ABILIFY MAINTENA$124
- ABILIFY ASIMTUFII$124
- INVEGA SUSTENNA$124
How this compares
$3,374 in reported general payments places this provider in the 80th percentile of 565 psychiatric/mental health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 17 | $60,864 |
| VivitrolNaltrexone Microspheres | 19 | $32,135 |
| VraylarCariprazine Hcl | 11 | $14,932 |
| Gabapentin | 28 | $602 |
| Duloxetine Hcl | 14 | $545 |
| Lurasidone Hcl | 12 | $516 |
| Hydroxyzine Pamoate | 26 | $499 |
| Fluoxetine Hcl | 26 | $469 |
| Olanzapine | 14 | $350 |
| Bupropion XlBupropion Hcl | 18 | $340 |
| Trazodone Hcl | 32 | $313 |
| Buspirone Hcl | 12 | $249 |
| Quetiapine Fumarate | 16 | $204 |
| Escitalopram Oxalate | 24 | $177 |
| Sertraline Hcl | 18 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Vivitrol | $229 | $92,99936 claims |
| AbbVieVraylar | $349 | $14,93211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Saint Joseph
- Deena SheltonSaint Joseph$7K
- Amy TallySaint Joseph$6K
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
- Matthew LindquistSt Louis$42K
- Stacy EmersonKennett$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.